Cowen and Company reiterated their outperform rating on shares of Dynavax Technologies Corporation (NASDAQ:DVAX) in a research report sent to investors on Thursday morning. Cowen and Company currently has a $45.00 target price on the biopharmaceutical company’s stock.

A number of other analysts have also recently commented on the company. William Blair reiterated an outperform rating on shares of Dynavax Technologies Corporation in a research report on Thursday. Royal Bank Of Canada set a $7.00 price objective on Dynavax Technologies Corporation and gave the company a hold rating in a research report on Wednesday, July 26th. Zacks Investment Research cut Dynavax Technologies Corporation from a buy rating to a hold rating in a research report on Tuesday, July 11th. Finally, ValuEngine cut Dynavax Technologies Corporation from a sell rating to a strong sell rating in a research report on Friday, June 2nd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. The company currently has a consensus rating of Buy and an average price target of $23.67.

Shares of Dynavax Technologies Corporation (DVAX) traded up 71.35% during midday trading on Thursday, reaching $15.85. The company had a trading volume of 23,030,935 shares. The company’s 50-day moving average is $9.29 and its 200-day moving average is $6.25. The stock’s market capitalization is $773.37 million. Dynavax Technologies Corporation has a 1-year low of $3.20 and a 1-year high of $17.50.

Dynavax Technologies Corporation (NASDAQ:DVAX) last posted its quarterly earnings data on Monday, May 8th. The biopharmaceutical company reported ($0.60) EPS for the quarter, meeting analysts’ consensus estimates of ($0.60). The company had revenue of $0.15 million during the quarter, compared to analysts’ expectations of $0.75 million. Dynavax Technologies Corporation had a negative return on equity of 100.45% and a negative net margin of 1,080.18%. During the same quarter in the prior year, the business earned ($0.70) earnings per share. On average, equities research analysts forecast that Dynavax Technologies Corporation will post ($1.47) EPS for the current year.

WARNING: “Dynavax Technologies Corporation’s (NASDAQ:DVAX) Outperform Rating Reiterated at Cowen and Company” was published by Watch List News and is owned by of Watch List News. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The original version of this news story can be accessed at https://www.watchlistnews.com/dynavax-technologies-corporations-nasdaqdvax-outperform-rating-reiterated-at-cowen-and-company/1464549.html.

A number of hedge funds have recently modified their holdings of DVAX. Candriam Luxembourg S.C.A. bought a new stake in shares of Dynavax Technologies Corporation during the second quarter worth approximately $5,066,000. CAPROCK Group Inc. bought a new stake in shares of Dynavax Technologies Corporation during the second quarter worth approximately $134,000. Kornitzer Capital Management Inc. KS boosted its stake in shares of Dynavax Technologies Corporation by 4.0% in the second quarter. Kornitzer Capital Management Inc. KS now owns 1,142,360 shares of the biopharmaceutical company’s stock worth $11,024,000 after buying an additional 43,850 shares during the last quarter. Russell Investments Group Ltd. boosted its stake in shares of Dynavax Technologies Corporation by 24.0% in the second quarter. Russell Investments Group Ltd. now owns 155,095 shares of the biopharmaceutical company’s stock worth $1,496,000 after buying an additional 30,036 shares during the last quarter. Finally, Creative Planning boosted its stake in shares of Dynavax Technologies Corporation by 4,181.6% in the second quarter. Creative Planning now owns 147,200 shares of the biopharmaceutical company’s stock worth $1,420,000 after buying an additional 143,762 shares during the last quarter. Institutional investors and hedge funds own 54.94% of the company’s stock.

Dynavax Technologies Corporation Company Profile

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.